Aim: The aim of the study was to investigate of the effectiveness of standard anti-anemic therapy for patients with anemia in the presence of chronic kidney disease treated with program hemodialysis. Material and research methods. 120 patients with CKD V and anemia receiving programmed hemodialysis were included into study. The inclusion criterion was a hemoglobin concentration below 10 g/dl. After the initial examination, all patients in a planned manner for an antianemic purpose took an oral iron 1 tablet per day once and EPS (recombinant erythropoietin beta) 50mU/kg intravenously with each hemodialysis procedure. Patients were examined for the presence and nature of anemia. In addition, serum iron, ferritin, and transferrin iron concentrations were estimated. Laboratory data obtained in a cohort of healthy volunteers within the 95% confidence interval were used as reference values. A month after inclusion in the study, all patients underwent a repeated hematological analysis, according to the results of which groups with achieved blood hemoglobin level of 12g/dl and higher (good hematological response) and below 12g/dl (insufficient hematological response) were isolated. Conclusion: in patients with CKD with anemia, it has a normochromic and normocytic character with signs of red blood cell anisocytosis. The use of an oral iron preparation and recombinant erythropoietin alpha within a month revealed two types of response - an increase in hemoglobin concentration to 12g/d l or more and failure to achieve the target concentration of heglobin (resistance to standard treatment for EPS), which was found in 72.5% of patients. The prognostic factor in the development of resistance to antianemic therapy is the duration of program hemodialysis (in the present study, 24 months or more). [ABSTRACT FROM AUTHOR]